Omalizumab chronic spontaneous urticaria: Efficacy, safety, predictors of treatment outcome, and time to response

Italian OCUReL Study Group, Eustachio Nettis, Luca Cegolon, Elisabetta Di Leo, Fabio Lodi Rizzini, Aikaterini Detoraki, Giorgio Walter Canonica

Research output: Contribution to journalArticle

Abstract

Background: Omalizumab is a recombinant anti-immunoglobulin E (IgE) antibody used in the treatment of patients with chronic spontaneous urticaria (CSU). Objective: This multicentric study assessed the safety and efficacy of omalizumab in patients (n=322) with CSU refractory to second-generation antihistamines, also investigating predictors of poor treatment outcome and time lag to response to anti-IgE therapy by serum auto-reactivity. Methods: This retrospective observational study comprised a 4-week pretreatment period, a 24-week treatment period with omalizumab (300 mg/month), and a 16-week follow-up period. Primary efficacy endpoints were mean and median change in 7-day urticaria activity score (UAS7), weekly itch severity score (ISS), and hive score from baseline to 4-, 12-, and 24-week values. Secondary endpoints included the proportion of patients (defined “responders”) with well-controlled urticaria (UAS7 ≤ 6) and complete treatment response (UAS7=0). Safety in terms of side effects was also assessed. Results: Omalizumab significantly and consistently reduced the mean UAS7, ISS, and hive score from baseline to weeks 4, 12, and 24, with a clear decreasing trend over time. At the end of the treatment period (week 24), 84.2% of patients had a UAS7 score of 6 or less and 66.7% had a UAS7 of 0. Higher pretreatment IgE levels were less likely to be associated with poor treatment response (ie, UAS7 > 6). Patients with a positive autologus serum skin test (ASST) were significantly more likely to be “slow responders” to omalizumab treatment (ie, response beyond 8 days since omalizumab administration) than ASST-negative patients (P
Original languageEnglish
Pages (from-to)474-478
Number of pages5
JournalAnnals of Allergy, Asthma and Immunology
Volume121
Issue number4
DOIs
Publication statusPublished - Oct 1 2018

Fingerprint

Urticaria
Safety
Immunoglobulin E
Skin Tests
Therapeutics
Non-Sedating Histamine H1 Antagonists
Serum
Passive Immunization
Observational Studies
Omalizumab
Retrospective Studies
Antibodies

Cite this

Omalizumab chronic spontaneous urticaria : Efficacy, safety, predictors of treatment outcome, and time to response. / Group, Italian OCUReL Study; Nettis, Eustachio; Cegolon, Luca; Di Leo, Elisabetta; Lodi Rizzini, Fabio; Detoraki, Aikaterini; Canonica, Giorgio Walter.

In: Annals of Allergy, Asthma and Immunology, Vol. 121, No. 4, 01.10.2018, p. 474-478.

Research output: Contribution to journalArticle

Group, Italian OCUReL Study ; Nettis, Eustachio ; Cegolon, Luca ; Di Leo, Elisabetta ; Lodi Rizzini, Fabio ; Detoraki, Aikaterini ; Canonica, Giorgio Walter. / Omalizumab chronic spontaneous urticaria : Efficacy, safety, predictors of treatment outcome, and time to response. In: Annals of Allergy, Asthma and Immunology. 2018 ; Vol. 121, No. 4. pp. 474-478.
@article{d49273a1990143c4bac7d942e125a133,
title = "Omalizumab chronic spontaneous urticaria: Efficacy, safety, predictors of treatment outcome, and time to response",
abstract = "Background: Omalizumab is a recombinant anti-immunoglobulin E (IgE) antibody used in the treatment of patients with chronic spontaneous urticaria (CSU). Objective: This multicentric study assessed the safety and efficacy of omalizumab in patients (n=322) with CSU refractory to second-generation antihistamines, also investigating predictors of poor treatment outcome and time lag to response to anti-IgE therapy by serum auto-reactivity. Methods: This retrospective observational study comprised a 4-week pretreatment period, a 24-week treatment period with omalizumab (300 mg/month), and a 16-week follow-up period. Primary efficacy endpoints were mean and median change in 7-day urticaria activity score (UAS7), weekly itch severity score (ISS), and hive score from baseline to 4-, 12-, and 24-week values. Secondary endpoints included the proportion of patients (defined “responders”) with well-controlled urticaria (UAS7 ≤ 6) and complete treatment response (UAS7=0). Safety in terms of side effects was also assessed. Results: Omalizumab significantly and consistently reduced the mean UAS7, ISS, and hive score from baseline to weeks 4, 12, and 24, with a clear decreasing trend over time. At the end of the treatment period (week 24), 84.2{\%} of patients had a UAS7 score of 6 or less and 66.7{\%} had a UAS7 of 0. Higher pretreatment IgE levels were less likely to be associated with poor treatment response (ie, UAS7 > 6). Patients with a positive autologus serum skin test (ASST) were significantly more likely to be “slow responders” to omalizumab treatment (ie, response beyond 8 days since omalizumab administration) than ASST-negative patients (P",
author = "Group, {Italian OCUReL Study} and Eustachio Nettis and Luca Cegolon and {Di Leo}, Elisabetta and {Lodi Rizzini}, Fabio and Aikaterini Detoraki and Canonica, {Giorgio Walter}",
year = "2018",
month = "10",
day = "1",
doi = "10.1016/j.anai.2018.06.014",
language = "English",
volume = "121",
pages = "474--478",
journal = "Annals of Allergy, Asthma and Immunology",
issn = "1081-1206",
publisher = "American College of Allergy, Asthma and Immunology",
number = "4",

}

TY - JOUR

T1 - Omalizumab chronic spontaneous urticaria

T2 - Efficacy, safety, predictors of treatment outcome, and time to response

AU - Group, Italian OCUReL Study

AU - Nettis, Eustachio

AU - Cegolon, Luca

AU - Di Leo, Elisabetta

AU - Lodi Rizzini, Fabio

AU - Detoraki, Aikaterini

AU - Canonica, Giorgio Walter

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Background: Omalizumab is a recombinant anti-immunoglobulin E (IgE) antibody used in the treatment of patients with chronic spontaneous urticaria (CSU). Objective: This multicentric study assessed the safety and efficacy of omalizumab in patients (n=322) with CSU refractory to second-generation antihistamines, also investigating predictors of poor treatment outcome and time lag to response to anti-IgE therapy by serum auto-reactivity. Methods: This retrospective observational study comprised a 4-week pretreatment period, a 24-week treatment period with omalizumab (300 mg/month), and a 16-week follow-up period. Primary efficacy endpoints were mean and median change in 7-day urticaria activity score (UAS7), weekly itch severity score (ISS), and hive score from baseline to 4-, 12-, and 24-week values. Secondary endpoints included the proportion of patients (defined “responders”) with well-controlled urticaria (UAS7 ≤ 6) and complete treatment response (UAS7=0). Safety in terms of side effects was also assessed. Results: Omalizumab significantly and consistently reduced the mean UAS7, ISS, and hive score from baseline to weeks 4, 12, and 24, with a clear decreasing trend over time. At the end of the treatment period (week 24), 84.2% of patients had a UAS7 score of 6 or less and 66.7% had a UAS7 of 0. Higher pretreatment IgE levels were less likely to be associated with poor treatment response (ie, UAS7 > 6). Patients with a positive autologus serum skin test (ASST) were significantly more likely to be “slow responders” to omalizumab treatment (ie, response beyond 8 days since omalizumab administration) than ASST-negative patients (P

AB - Background: Omalizumab is a recombinant anti-immunoglobulin E (IgE) antibody used in the treatment of patients with chronic spontaneous urticaria (CSU). Objective: This multicentric study assessed the safety and efficacy of omalizumab in patients (n=322) with CSU refractory to second-generation antihistamines, also investigating predictors of poor treatment outcome and time lag to response to anti-IgE therapy by serum auto-reactivity. Methods: This retrospective observational study comprised a 4-week pretreatment period, a 24-week treatment period with omalizumab (300 mg/month), and a 16-week follow-up period. Primary efficacy endpoints were mean and median change in 7-day urticaria activity score (UAS7), weekly itch severity score (ISS), and hive score from baseline to 4-, 12-, and 24-week values. Secondary endpoints included the proportion of patients (defined “responders”) with well-controlled urticaria (UAS7 ≤ 6) and complete treatment response (UAS7=0). Safety in terms of side effects was also assessed. Results: Omalizumab significantly and consistently reduced the mean UAS7, ISS, and hive score from baseline to weeks 4, 12, and 24, with a clear decreasing trend over time. At the end of the treatment period (week 24), 84.2% of patients had a UAS7 score of 6 or less and 66.7% had a UAS7 of 0. Higher pretreatment IgE levels were less likely to be associated with poor treatment response (ie, UAS7 > 6). Patients with a positive autologus serum skin test (ASST) were significantly more likely to be “slow responders” to omalizumab treatment (ie, response beyond 8 days since omalizumab administration) than ASST-negative patients (P

U2 - 10.1016/j.anai.2018.06.014

DO - 10.1016/j.anai.2018.06.014

M3 - Article

VL - 121

SP - 474

EP - 478

JO - Annals of Allergy, Asthma and Immunology

JF - Annals of Allergy, Asthma and Immunology

SN - 1081-1206

IS - 4

ER -